Evercore ISI Group Upgrades Vertex Pharmaceuticals to Outperform, Announces $438 Price Target
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko upgraded Vertex Pharmaceuticals (VRTX) from In-Line to Outperform with a new price target of $438.
April 11, 2024 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals upgraded by Evercore ISI to Outperform with a $438 price target, indicating strong future performance expectations.
Upgrades by prominent analysts like Evercore ISI often lead to increased investor confidence and can drive stock prices up in the short term. The substantial raise in the price target to $438 from a previous In-Line rating suggests a strong bullish outlook for Vertex Pharmaceuticals, likely influencing investor sentiment positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100